Nymox Pharmaceutical Corp Il valore contabile della azione
Cos'è Il valore contabile della azione di Nymox Pharmaceutical Corp?
Il valore contabile della azione di Nymox Pharmaceutical Corp è 0.01
Qual è la definizione di Il valore contabile della azione?
Il valore contabile per azione è l'asset di una società meno le passività diviso per il numero di azioni in circolazione.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Il valore contabile della azione di aziende nel Health Care settore su NASDAQ rispetto a Nymox Pharmaceutical Corp
Cosa fa Nymox Pharmaceutical Corp?
nymox pharmaceutical corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. its lead drug candidate is fexapotide triflutate (nx-1207) that has completed phase iii clinical trials for the treatment of benign prostatic hyperplasia; and is in phase ii clinical trial for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. the company also develops and markets nicalert and tobacalert test strips that use urine or saliva to detect use of tobacco products. in addition, it offers alzheimalert, a proprietary urine assay that aids physicians in the diagnosis of alzheimer's disease. the company operates in canada, the united states, europe, and internationally. nymox pharmaceutical corporation was founded in 1989 and is headquartered in nassau, bahamas.
Aziende con il valore contabile della azione simili a Nymox Pharmaceutical Corp
- Sulliden Mining Capital ha Il valore contabile della azione di 0.01
- Metro Mining ha Il valore contabile della azione di 0.01
- Code Agriculture () ha Il valore contabile della azione di 0.01
- Avenira ha Il valore contabile della azione di 0.01
- Voyageur Pharmaceuticals ha Il valore contabile della azione di 0.01
- KORE Mining ha Il valore contabile della azione di 0.01
- Nymox Pharmaceutical Corp ha Il valore contabile della azione di 0.01
- Battery Minerals ha Il valore contabile della azione di 0.01
- Metalsearch ha Il valore contabile della azione di 0.01
- Versarien plc ha Il valore contabile della azione di 0.01
- Fuse Cobalt Inc ha Il valore contabile della azione di 0.01
- Resolve Ventures ha Il valore contabile della azione di 0.01
- WLS ha Il valore contabile della azione di 0.01